Literature DB >> 10652480

Antisense therapeutics: is it as simple as complementary base recognition?

S Agrawal1, E R Kandimalla.   

Abstract

Antisense oligonucleotides provide a simple and efficient approach for developing target-selective drugs because they can modulate gene expression sequence-specifically. Antisense oligonucleotides have also become efficient molecular biological tools to investigate the function of any protein in the cell. As the application of antisense oligonucleotides has expanded, multiple mechanisms of oligonucleotides have been characterized that impede their routine use. Here, we discuss different mechanisms of action of oligonucleotides and the possible ways of minimizing non-antisense-related [corrected] effects to improve their specificity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652480     DOI: 10.1016/s1357-4310(99)01638-x

Source DB:  PubMed          Journal:  Mol Med Today        ISSN: 1357-4310


  15 in total

1.  Intravitreal treatment with antisense oligonucleotides targeting tumor necrosis factor-α in murine herpes simplex virus type 1 retinitis.

Authors:  Rafael S Grajewski; Jin Li; Susanne Wasmuth; Maren Hennig; Dirk Bauer; Arnd Heiligenhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-10       Impact factor: 3.117

2.  Quantitative assessment of chimeraplast stability in biological fluids by polyacrylamide gel electrophoresis and laser-assisted fluorescence analysis.

Authors:  David de Semir; Anna Avinyó; Sara Larriba; Virginia Nunes; Teresa Casals; Xavier Estivill; Josep M Aran
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

Review 3.  Gene modulation for treating liver fibrosis.

Authors:  Kun Cheng; Ram I Mahato
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  2007       Impact factor: 4.889

4.  The application of antisense technology to medicine.

Authors:  R Re
Journal:  Ochsner J       Date:  2000-10

Review 5.  Genetically engineered intracellular single-chain antibodies in gene therapy.

Authors:  Guadalupe Bilbao; Juan Luis Contreras; David T Curiel
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

6.  Identification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors.

Authors:  Maurice Phil DeYoung; Matthew Tress; Ramaswamy Narayanan
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-03       Impact factor: 11.205

7.  Immunostimulatory properties of phosphorothioate CpG DNA containing both 3'-5'- and 2'-5'-internucleotide linkages.

Authors:  Dong Yu; Ekambar R Kandimalla; Qiuyan Zhao; Yanping Cong; Sudhir Agrawal
Journal:  Nucleic Acids Res       Date:  2002-04-01       Impact factor: 16.971

8.  Inhibition of MDR1 gene expression by chimeric HNA antisense oligonucleotides.

Authors:  Hyunmin Kang; Michael H Fisher; Dong Xu; Yuko J Miyamoto; Arnaud Marchand; Arthur Van Aerschot; Piet Herdewijn; Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2004-08-17       Impact factor: 16.971

9.  Subconjunctival antisense oligonucleotides targeting TNF-alpha influence immunopathology and viral replication in murine HSV-1 retinitis.

Authors:  Jin Li; Susanne Wasmuth; Dirk Bauer; Hanna Baehler; Maren Hennig; Arnd Heiligenhaus
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-05-20       Impact factor: 3.117

10.  Silencing of the aspergillopepsin B (pepB) gene of Aspergillus awamori by antisense RNA expression or protease removal by gene disruption results in a large increase in thaumatin production.

Authors:  Francisco J Moralejo; Rosa Elena Cardoza; Santiago Gutierrez; Marta Lombraña; Francisco Fierro; Juan F Martín
Journal:  Appl Environ Microbiol       Date:  2002-07       Impact factor: 4.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.